News Scotland's Opdivo decision sparks funding row Patients in Scotland will receive lung cancer drug, those in England will not.
News AZ pays Heptares $10m as cancer trial begins Phase 1 study of immuno-oncology drug candidate begins.
R&D BMS looks for cancer combos with Cormorant buy Bristol searching for new immuno-oncology combinations.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
